TCBP TC BioPharm Ltd: מקדם חוב לטווח ארוך להון

TC Biopharm is developing a unique environment for combating tumors using specific T-cells and closed medical protocols. This daily price chart reflects the asset's dynamics, where the indicator stands at 0.63. TC Biopharm is targeting the massive leukemia therapy segment by expanding the number of trials. Management is focused on creating advanced treatments for infections and cancer, leveraging its own scientific research.

For TC Biopharm, analyzing the debt load is critical when assessing the resilience of this defensive asset. This long-term debt-to-equity ratio compares the volume of loans with maturities exceeding one year against the total equity. The metric reveals hidden liquidity deficits, preventing investments in "value traps." Stable demand for unique medical developments minimizes debt service risks. A low indicator level confirms the company's financial autonomy within the sovereign cycle.